Vivas, DavidRoldán, VanessaEsteve-Pastor, María AsunciónRoldán, InmaculadaTello-Montoliu, AntonioRuiz-Nodar, Juan MiguelCosín-Sales, JuanGámez, José MaríaConsuegra, LucianoFerreiro, José LuisMarín, FranciscoRevisores expertos2023-02-082023-02-082020-04-22http://hdl.handle.net/10668/15423The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.esAntithromboticsCOVID-19CoronavirusSARS-CoV-2Thrombosisresearch article32327870open access10.1016/j.recesp.2020.04.0061579-2242PMC7176384https://doi.org/10.1016/j.recesp.2020.04.006https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176384/pdf